InterMune IPF drug enters Phase III
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
InterMune commences enrollment of Phase III CAPACITY program evaluating pirfenidone for treatment of idiopathic pulmonary fibrosis (IPF), the firm says April 27. The dual-trial program "will advance relatively quickly and conclude toward the end of 2007," CEO Dan Welch states. Top-line data are expected in early 2009. InterMune finalized the studies' designs with FDA last fall; the company has pointed to CAPACITY as the first IPF program to utilize lung function as the primary endpoint (1Pharmaceutical Approvals Monthly November 2005, p. 6). Pirfenidone is a small molecule p38-gamma inhibitor. Other firms developing IPF treatments include Actelion, CoTherix and Novartis...
You may also be interested in...
InterMune Plans Pirfenidone Pulmonary Fibrosis Phase III Study In 2006
InterMune's pivotal trials of pirfenidone will be the first Phase III studies of an idiopathic pulmonary fibrosis drug to use the primary endpoint of lung function as measured by change in forced vital capacity
Investors Go Beserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.